Search results for "Concomitant"

showing 10 items of 248 documents

Adjuvant Intravesical Chemotherapy in Patients with Primary T1 G3 Transitional Cell Carcinoma of the Bladder

1993

The Authors present their experience with TUR plus adjuvant intravesical chemotherapy in 50 patients affected by primary T1 G3 bladder tumours without previous or concomitant carcinoma in situ. At a mean follow-up of 36 months, 84% of the patients are alive and tumour-free. Cystectomy was performed in three patients due to locally invasive disease. Five patients (10%) died of bladder cancer.

medicine.medical_specialtybusiness.industryCarcinoma in situmedicine.medical_treatmentUrologyGeneral Medicinemedicine.diseaseTransitional cell carcinomaConcomitantMedicineIn patientbusinessIntravesical chemotherapyAdjuvantUrologia Journal
researchProduct

Adjunctive Brivaracetam in Focal Epilepsy: Real-World Evidence from the BRIVAracetam add-on First Italian netwoRk STudy (BRIVAFIRST)

2021

Background: In randomized controlled trials, add-on brivaracetam (BRV) reduced seizure frequency in patients with drug-resistant focal epilepsy. Studies performed in a naturalistic setting are a useful complement to characterize the drug profile. Objective: This multicentre study assessed the effectiveness and tolerability of adjunctive BRV in a large population of patients with focal epilepsy in the context of real-world clinical practice. Methods: The BRIVAFIRST (BRIVAracetam add-on First Italian netwoRk STudy) was a retrospective, multicentre study including adult patients prescribed adjunctive BRV. Patients with focal epilepsy and 12-month follow-up were considered. Main outcomes includ…

medicine.medical_specialtybusiness.industryContext (language use)Brivaracetammedicine.diseaseDiscontinuationlaw.inventionPsychiatry and Mental healthEpilepsyRandomized controlled trialTolerabilityfocal epilepsy add-on therapy seizurelawConcomitantInternal medicineMedicinePharmacology (medical)Neurology (clinical)LevetiracetamOriginal Research Articlebusinessmedicine.drug
researchProduct

Evaluation of early and late histamine release by three standard volume substitutes

2001

Following meta-analysis [1], the use of colloidal solutions in intensive care medicine is under discussion. Although polygeline [2] and human albumin are known to cause histamine release, other substances eg hydroxyethyl starch were thought to be without effect. Histamine release depends on the clinical scenario, concomitant drugs, infusion speed, duration and amount of infusion. However, there is no information about their effect regarding time periods longer than immediate reactions. This study investigated the histamine releasing effects of three plasma substitutes administered and observed over a longer period of time, simulating many of the clinical scenarios.

medicine.medical_specialtybusiness.industryHuman albuminPharmacologyHydroxyethyl starchCritical Care and Intensive Care MedicinePlasma Substituteschemistry.chemical_compoundchemistryConcomitantPolygelineEmergency medicineMeeting AbstractmedicinebusinessClinical scenarioHistaminemedicine.drugCritical Care
researchProduct

Symptomatic and Ancillary Therapy

2010

Although enzyme replacement therapy has had a considerable impact on the management of patients with Fabry disease, it is essential that attention is also given to supportive therapy. In this chapter a general overview about ancillary therapy is given. The great variability of clinical symptoms faced by patients with Fabry disease need the involvement from many different specialists, as well as a wide range of concomitant treatments. Coordinating a good multidisciplinary approach for each patient and ensuring that treatment is made as convenient as possible may offer a more positive impact on the quality of life of those patients affected by Fabry disease.

medicine.medical_specialtybusiness.industryMultidisciplinary approachSupportive psychotherapyConcomitantmedicineEnzyme replacement therapyIntensive care medicinebusinessmedicine.diseaseFabry disease
researchProduct

Ergebnisse der bilateralen Operationstechnik bei primärem Hyperparathyreoidismus

2001

AIM OF THE STUDY The surgical success rate and clinical outcome after surgery for primary hyperparathyroidism were evaluated in a prospective long-term follow-up study. PATIENTS AND METHODS 407 patients, 396 with the first manifestation, 6 with recurrent and 5 with persistent disease underwent operation from August 1, 1987 to August 15, 1999. All patients were prospectively investigated in a long-term follow-up study and underwent reexaminations at regular surveillance intervals. The postoperative course is known in 93.9% of all patients. RESULTS The prevalence of asymptomatic primary hyperparathyroidism was 5.6% in our patients. Surgical cure was obtained in 97.7% of patients after initial…

medicine.medical_specialtybusiness.industryThyroidmedicine.diseaseAsymptomaticSurgeryResectionPersistent Diseasemedicine.anatomical_structureNeck explorationConcomitantMedicineSurgeryParathyroid surgerymedicine.symptombusinessPrimary hyperparathyroidismZentralblatt für Chirurgie
researchProduct

Acute myocardial infarction occurring in versus out of the hospital: patient characteristics and clinical outcome

2000

OBJECTIVES We describe the baseline characteristics and clinical course of patients who had an acute myocardial infarction (AMI) during their hospital stay. BACKGROUND In comparison with patients who had an AMI outside of the hospital (prehospital AMI), the data on patients who had an AMI in the hospital are poorly described. METHODS Patients with an in-hospital AMI were prospectively registered in the Southwest German Maximal Individual TheRapy in Acute myocardial infarction (MITRA) study and compared with patients with prehospital AMI. RESULTS Of 5,888 patients with AMI, 403 patients (6.8%) had an in-hospital AMI. These patients were older, more often male and sicker as compared with the …

medicine.medical_specialtybusiness.industryhealth care facilities manpower and servicesmedicine.medical_treatmentOdds ratioThrombolysismedicine.diseaseConfidence intervalSurgeryReperfusion therapyInternal medicineConcomitantDiabetes mellitusCardiologyMedicinecardiovascular diseasesMyocardial infarctionCardiology and Cardiovascular MedicinebusinessProspective cohort studyhealth care economics and organizationsJournal of the American College of Cardiology
researchProduct

Diagnostik und operative Therapie von Phäochromozytomen und Paragangliomen

2010

Pheochromocytomas and paragangliomas are rare chromaffin tumours that represent an exceptional challenge for the surgeon because of the concomitant secretion of catecholamines. Recent findings on the genetic background of hereditary tumours have challenged the rule of the 10 % -tumour and significantly changed the requirements for preoperative work-up and surgical strategy. Early detection of malignant growth or multiple hereditary tumours is the goal of imaging techniques such as CT/MRI, (123)I-MIBG-(SPECT) or (18)F-DOPA-PET. However, in the absence of metastasis, reliable differentiation between -benign and malignant growth is preoperatively and even histopathologically rarely possible. A…

medicine.medical_specialtybusiness.industrymedicine.medical_treatmentDebulkingmedicine.diseaseDiaphragm (structural system)MetastasisEndocrine surgeryPheochromocytomaParagangliomaConcomitantmedicineSurgeryRadiologybusinessAbdominal surgeryZentralblatt für Chirurgie
researchProduct

Bortezomib Retreatment in Relapsed Multiple Myeloma (MM): Results from a Binational, Multicenter Retrospective Survey

2008

Abstract In myeloma therapy retreatment after successful therapy is frequently considered. Here we present pooled data from a German and Swiss multicenter, retrospective survey (26866138MMY4014). The survey started in Germany and was later extended to Switzerland. German data have already been published before. Here we report on the entire cohort of patients for the first time. For inclusion into this analysis, patients with MM had to have had preceding bortezomib treatment, resulting in at least partial remission and a second therapy with Bortezomib on relapse. The intention of this trial was to provide further evidence of the value of a retreatment with bortezomib, description of predispo…

medicine.medical_specialtyeducation.field_of_studyIntention-to-treat analysisBortezomibbusiness.industryImmunologyPopulationCell BiologyHematologymedicine.diseaseBiochemistrySurgeryTransplantationConcomitantInternal medicinemedicineAdverse effecteducationbusinessMultiple myelomaDexamethasonemedicine.drugBlood
researchProduct

Humeral Shaft Fractures

2014

Humeral shaft fractures account for approximately 7 % of all fractures in adults. They occur after direct trauma such as traffic accidents or after indirect, rotational trauma in sports accidents or falls at home. There are two peaks of incidence in the adult population: the young male and the older female. The first patient typically is the victim of high-energy trauma with multiple lesions, a more severe humeral fracture type and concomitant soft tissue damage. The latter patient suffers a solitary lesion and is the victim of a low-energy accident such as a fall from a standing or sitting position. The fracture type is then simple and there is no or minimal soft tissue damage. As pain is …

medicine.medical_specialtyeducation.field_of_studybusiness.industryIncidence (epidemiology)PopulationSoft tissueSittingSurgeryConcomitantDeltoid muscleHumeral shaftmedicineeducationbusinessRadial nerve
researchProduct

Early Spot Urinary Sodium and Diuretic Efficiency in Acute Heart Failure and Concomitant Renal Dysfunction

2020

<b><i>Objective:</i></b> In acute heart failure (AHF), early assessment of spot urinary sodium (U<sub>Na</sub>) has emerged as a useful biomarker for risk stratification and monitoring. The objective of this study was to investigate (a) whether early spot U<sub>Na</sub> predicts 24-h diuretic efficiency and (b) the clinical factors associated with early spot U<sub>Na</sub> in patients with AHF and concomitant renal dysfunction (RD). <b><i>Methods:</i></b> This is a post hoc analysis of the IMPROVE-HF trial, in which 160 patients with AHF and RD (estimated glomerular filtrate rate [eGFR] <60 mL/min/1…

medicine.medical_specialtymedicine.drug_classUrologymedicine.medical_treatmentUrologyInterquartile rangePost-hoc analysismedicineNatriuretic peptideHumansDiureticsAgedAged 80 and overHeart Failurebusiness.industrySodiumFurosemidemedicine.diseaseHeart failureConcomitantAcute DiseasePopulation studyKidney DiseasesDiureticCardiology and Cardiovascular Medicinebusinessmedicine.drugCardiorenal Medicine
researchProduct